Skip to main content
Premium Trial:

Request an Annual Quote

Beyond Genomics and GSK in Metabolic Disease Research Collaboration

NEW YORK, Jan. 28 (GenomeWeb News) -- Beyond Genomics of Waltham, Mass, and GlaxoSmithKline today announced a research collaboration for drug discovery and development in metabolic diseases, following a pilot project that began in December 2002, the companies said in a statement.

 

Under the agreement, GSK will pay Beyond Genomics an undisclosed upfront fee and will fund the research program for its full term. Additional financial terms of the agreement were not disclosed. The agreement includes options and license agreements.

Beyond Genomics will apply its technology to elucidate disease pathways and identify biomarkers of disease state and drug response using its systems biology approach, which includes its molecular phenotyping platform to simultaneously measure transcripts, proteins, and metabolites, and integrate the data sets produced with clinical information, according to the company.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.